相关实验视频

Updated: Jan 10, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

连续的TIL输液和PD-1阻断驱动长期的克隆性持续性在前列腺癌中

Lucas C M Arruda^1,2, Julia Karbach³, Dragan Kiselicki³

¹Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.

Frontiers in oncology

|November 21, 2025

概括

瘤透淋巴细胞 (TIL) 治疗与PD-1阻断相结合,在转移性前列腺癌中显示出长期的疗效. 纵向T细胞受体测序显示了持续的TIL持久性和与免疫治疗的协同作用.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
基因组学就是基因组学.

背景情况:

使用瘤透性淋巴细胞 (TIL) 的采用细胞疗法在转移性癌症中提供了持久的反应.
对于TIL治疗的长期克隆动态和与检查点阻塞的协同作用尚不清楚.

研究的目的:

研究瘤透淋巴细胞 (TIL) 的长期克隆动态及其与抗PD-1疗法的协同作用.
为了追踪T细胞受体 (TCR) 克隆型的持续性和演变,在患有转移性前列腺癌的患者中超过五年.

主要方法:

血液和瘤样本的纵向高通量T细胞受体 (TCR) 测序.
一个患有转移性前列腺癌的患者接受多次TIL输液和抗PD-1治疗的案例研究.

主要成果:

来自TIL的克隆类型在血液中长期存在,与临床反应相关的扩张.
多次TIL的使用改善了药理动力学特征.
与 pembrolizumab 的联合治疗导致了TIL 克隆类型的重新扩张和新克隆的出现.
克隆型稳定性在治疗后长达五年的时间内得到观察.

结论:

与PD-1阻断相结合的TIL治疗显示出强大的协同作用,增强了输注和内源T细胞反应.
纵向免疫基因组监测对于个性化免疫疗法策略有价值.
这些发现提供了对长期TIL持久性和抗瘤免疫的重新激活的见解.

关键词:

在TCR的NGS中.这是一种抗PD-1药物.免疫检查点封锁封锁这就是Pembrolizumab.瘤透性淋巴细胞 (TIL) 是一种

更多相关视频

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.